AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
AstraZeneca reports mixed lung cancer trial data, highlighting successes for Tagrisso and Enhertu while halting a volrustomig study.
AstraZeneca tested three new cancer medicines. Some worked really well, but one didn't work well enough to keep testing—so the company stopped it. When a medicine company gets some wins and some losses, it tells you they're still learning what works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.